In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma

In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma

IntroductionEpendymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who surv...

Full description

Bibliographic Details
Main Authors: Jacqueline P. Whitehouse, Hilary Hii, Chelsea Mayoh, Marie Wong, Pamela Ajuyah, Paulette Barahona, Louise Cui, Hetal Dholaria, Christine L. White, Molly K. Buntine, Jacob Byrne, Keteryne Rodrigues da Silva, Meegan Howlett, Emily J. Girard, Maria Tsoli, David S. Ziegler, Jason M. Dyke, Sharon Lee, Paul G. Ekert, Mark J. Cowley, Nicholas G. Gottardo, Raelene Endersby
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
ependymoma
posterior fossa
patient-derived
xenograft
molecular
pediatric cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1123492/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1123492/full

Similar Items